Hindi nagbibigay ng serbisyo ang XM sa mga residente ng Estados Unidos.

Hindi nagbibigay ng serbisyo ang XM sa mga residente ng Estados Unidos.
Z
Z

Zimmer

Balita

Reuters - 9 oras ang nakaraan

Australia's Osteopore surges on exclusive distribution agreement

BUZZ-Australia's Osteopore surges on exclusive distribution agreement ** Shares of medical technology firm Osteopore OSX.AX rise as much as 35.7% to A$0.076 ** Stock hits highest level, and posts its biggest intraday pct gain since June 6 ** Co says it signed an exclusive distribution agreement with a unit of Singapore-based Zimmer Biomet ZBH.N **
Z
Reuters - 2 linggo ang nakaraan

Zimmer Biomet Holdings On June 28, Got Into A New Five-Year Revolving Credit Agreement & New 364-Day Revolving Credit Agreement

BRIEF-Zimmer Biomet Holdings On June 28, Got Into A New Five-Year Revolving Credit Agreement & New 364-Day Revolving Credit Agreement July 1 (Reuters) - Zimmer Biomet Holdings Inc ZBH.N : ZIMMER BIOMET HOLDINGS: ON JUNE 28, GOT INTO A NEW FIVE-YEAR REVOLVING CREDIT AGREEMENT & NEW 364-DAY REVOLVING CREDIT AGREEMENT ZIMMER BIOMET HOLDINGS INC: FIVE-
Z
Reuters - 2 linggo ang nakaraan

U.S. AT&T, ATI, California Resources

U.S. RESEARCH ROUNDUP-AT&T, ATI, California Resources July 1 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including AT&T, ATI and California Resources, on Monday. HIGHLIGHTS * AT&T Inc T.N : JP Morgan adds stock to its U.S. analyst focus list * ATI Inc ATI.N : JP Morgan removes stock from its U.S.
A
I
N
W
H
Z
T
U
Reuters - 1 buwan ang nakaraan

RevelAi Health And Zimmer Biomet Announce Exclusive Multi-Year Co-Marketing Agreement To Advance Value-Based Care And Health Equity Through Powered Technology

BRIEF-RevelAi Health And Zimmer Biomet Announce Exclusive Multi-Year Co-Marketing Agreement To Advance Value-Based Care And Health Equity Through AI-Powered Technology June 12 (Reuters) - Zimmer Biomet Holdings Inc ZBH.N : REVELAI HEALTH AND ZIMMER BIOMET ANNOUNCE EXCLUSIVE MULTI-YEAR CO-MARKETING AGREEMENT TO ADVANCE VALUE-BASED CARE AND HEALTH EQ
Z
Reuters - 2 buwan ang nakaraan

Zimmer Biomet Holdings Inc Sees Mid-Single-Digit Percentage Constant Currency Consolidated Revenue Compound Annual Growth Rate For 2024 Through 2027

BRIEF-Zimmer Biomet Holdings Inc Sees Mid-Single-Digit Percentage Constant Currency Consolidated Revenue Compound Annual Growth Rate For 2024 Through 2027 Zimmer Biomet Holdings Inc ZBH.N : ZIMMER BIOMET HOLDINGS INC: SEES MID-SINGLE-DIGIT PERCENTAGE CONSTANT CURRENCY CONSOLIDATED REVENUE COMPOUND ANNUAL GROWTH RATE FOR 2024 THROUGH 2027 ZIMMER BIO
Z
Reuters - 2 buwan ang nakaraan

U.S. Paramount Global, Sprout Social, Williams-Sonoma

U.S. RESEARCH ROUNDUP- Paramount Global, Sprout Social, Williams-Sonoma May 3 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Paramount Global, Sprout Social and Williams-Sonoma ,on Friday. HIGHLIGHTS * Expedia Group Inc EXPE.O : Piper Sandler cuts to neutral from overweight * Paramount Global PARA.O : Seaport Research Partners cuts to neutral from buy * Sprout Social Inc SPT.O : Piper Sandler cuts to neutral from ov
A
A
B
B
C
E
F
H
S
D
T
B
Z
A
B
C
M
T
Reuters - 3 buwan ang nakaraan

Zimmer Biomet Holdings Inc reports results for the quarter ended in January - Earnings Summary

Zimmer Biomet Holdings Inc reports results for the quarter ended in January - Earnings Summary Zimmer Biomet Holdings Inc ZBH.N reported quarterly adjusted earnings of $1.94​​ per share for the quarter ended in January, higher than the same quarter last year, when the company reported EPS of $1.89. The mean expectation of twenty six analysts for the quarter was for earnings of $1.87 per share.
Z
Reuters - 3 buwan ang nakaraan

Zimmer Biomet beats Q1 profit estimates on robust demand for knee, hip devices

Zimmer Biomet beats Q1 profit estimates on robust demand for knee, hip devices May 2 (Reuters) - Medtech firm Zimmer Biomet Holdings ZBH.N beat Wall Street estimates for first-quarter profit on Thursday, on the back of robust demand for its devices that are used in knee and hip reconstruction procedures. Zimmer's results extend a strong quarter for medical device makers, including peer Stryker Corp SYK.N which raised its annual profit outlook betting on steady demand for its hip and knee implant
S
Z
Reuters - 3 buwan ang nakaraan

Zimmer Biomet Q1 Adjusted EPS USD 1.94 Vs. IBES Estimate USD 1.87

BRIEF-Zimmer Biomet Q1 Adjusted EPS USD 1.94 Vs. IBES Estimate USD 1.87 May 02 (Reuters) - Zimmer Biomet Q1 EPS USD 0.84. Q1 sales USD 1,889 million vs. IBES estimate USD 1,869 million
Z
Reuters - 3 buwan ang nakaraan

Fed QT taper calms the horses, yen pops again

MORNING BID AMERICAS-Fed QT taper calms the horses, yen pops again A look at the day ahead in U.S. and global markets from Mike Dolan Anxious bond traders seem to have taken solace from the Federal Reserve's surprisingly sharp brake on its "quantitative tightening" process on Wednesday, while the yen capitalized on an easier dollar after what seemed like the second bout of Japanese intervention this week.
A
A
A
C
E
H
I
R
S
U
A
U
I
V
W
Z
A
B
D
H
I
L
P
P
P
T
Reuters - 3 buwan ang nakaraan

Zimmer Biomet Holdings Inc <ZBH.N> expected to post earnings of $1.87 a share - Earnings Preview

Zimmer Biomet Holdings Inc expected to post earnings of $1.87 a share - Earnings Preview Zimmer Biomet Holdings Inc ZBH.N , ZBH is expected to show a rise in quarterly revenue when it reports results on May 2 for the period ending March 31 2024 The Warsaw Indiana Indiana-based company is expected to report a 2.1% increase in revenue to $1.869 billion from $1.83 billion a year ago, according to the mean estimate from 23 analysts, based on LSEG data.
Z
Reuters - 3 buwan ang nakaraan

Medical device makers fall after J&J's medtech unit misses sales estimates

BUZZ-Medical device makers fall after J&J's medtech unit misses sales estimates ** Shares of medical device makers fall between 1% and 3% after Johnson & Johnson's JNJ.N medical devices unit reports Q1 sales of $7.82 bln, missing Wall Street estimates of $7.88 bln, per LSEG data ** Stryker SYK.N down 1%, Zimmer Biomet ZBH.N down 1.2%, Medtronic MDT
A
B
S
Z
Reuters - 3 buwan ang nakaraan

J&J's medical device sales fall short, cancer drugs seen growing

UPDATE 5-J&J's medical device sales fall short, cancer drugs seen growing Recasts with focus on medical device sales miss, Adds investor call details in paragraphs 8-10 and 17, updates shares By Patrick Wingrove and Bhanvi Satija April 16 (Reuters) - Johnson & Johnson's JNJ.N first-quarter revenue missed Wall Street estimates for medical devices on Tuesday and sales of its blockbuster psoriasis drug Stelara came in lower than expected as the company prepares for its loss of exclusivity in the U.
S
Z

Kundisyon

Mga Patok na Assets

Disclaimer: Ang mga kabilang sa XM Group ay nagbibigay lang ng serbisyo sa pagpapatupad at pag-access sa aming Online Trading Facility, kung saan pinapahintulutan nito ang pagtingin at/o paggamit sa nilalaman na makikita sa website o sa pamamagitan nito, at walang layuning palitan o palawigin ito, at hindi din ito papalitan o papalawigin. Ang naturang pag-access at paggamit ay palaging alinsunod sa: (i) Mga Tuntunin at Kundisyon; (ii) Mga Babala sa Risk; at (iii) Kabuuang Disclaimer. Kaya naman ang naturang nilalaman ay ituturing na pangkalahatang impormasyon lamang. Mangyaring isaalang-alang na ang mga nilalaman ng aming Online Trading Facility ay hindi paglikom, o alok, para magsagawa ng anumang transaksyon sa mga pinansyal na market. Ang pag-trade sa alinmang pinansyal na market ay nagtataglay ng mataas na lebel ng risk sa iyong kapital.

Lahat ng materyales na nakalathala sa aming Online Trading Facility ay nakalaan para sa layuning edukasyonal/pang-impormasyon lamang at hindi naglalaman – at hindi dapat ituring bilang naglalaman – ng payo at rekomendasyon na pangpinansyal, tungkol sa buwis sa pag-i-invest, o pang-trade, o tala ng aming presyo sa pag-trade, o alok para sa, o paglikom ng, transaksyon sa alinmang pinansyal na instrument o hindi ginustong pinansyal na promosyon.

Sa anumang nilalaman na galing sa ikatlong partido, pati na ang mga nilalaman na inihanda ng XM, ang mga naturang opinyon, balita, pananaliksik, pag-analisa, presyo, ibang impormasyon o link sa ibang mga site na makikita sa website na ito ay ibibigay tulad ng nandoon, bilang pangkalahatang komentaryo sa market at hindi ito nagtataglay ng payo sa pag-i-invest. Kung ang alinmang nilalaman nito ay itinuring bilang pananaliksik sa pag-i-invest, kailangan mong isaalang-alang at tanggapin na hindi ito inilaan at inihanda alinsunod sa mga legal na pangangailangan na idinisenyo para maisulong ang pagsasarili ng pananaliksik sa pag-i-invest, at dahil dito ituturing ito na komunikasyon sa marketing sa ilalim ng mga kaugnay na batas at regulasyon. Mangyaring siguruhin na nabasa at naintindihan mo ang aming Notipikasyon sa Hindi Independyenteng Pananaliksik sa Pag-i-invest at Babala sa Risk na may kinalaman sa impormasyong nakalagay sa itaas, na maa-access dito.

Babala sa Risk: Maaaring malugi ang iyong kapital. Maaaring hindi nababagay sa lahat ang mga produktong naka-leverage. Mangyaring isaalang-alang ang aming Pahayag sa Risk.